P. Lanzetta ITALY

15:00 Welcome

J-F. Korobelnik FRANCE

15:02 A global non-interventional study of real-world proactive regimens with intravitreal aflibercept in patients with nAMD: XTEND study Year 1 primary analysis

A. Loewenstein ISRAEL

15:07 Global perspectives of patients and healthcare professionals on the challenges of managing nAMD in clinical practice: An interim analysis

S. Schmitz-Valckenberg USA

15:12 Quantification of Lesion Progression of Incomplete and Complete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration.

P. Lanzetta ITALY

15:17 Evaluation of 8 mg intravitreal aflibercept for neovascular age-related macular degeneration: Results from the Phase 2 CANDELA study

C. Delcourt FRANCE

15:22 Age-related macular degeneration and loss of autonomy : the Alienor-3C Study

J.M. Ruiz-Moreno SPAIN

15:27 Serum 25-hydroxy vitamin D levels in age-related macular degeneration.

C. Farinha PORTUGAL

15:32 Phenotypic expression of CFH rare variants in Age-related Macular Degeneration patients.

N. Eter GERMANY

15:37 Characterization of macular neovascularization subtypes in age-related macular degeneration to optimize treatment outcomes

R. Hogg UK

15:42 Monitoring for neovascular Age-related macular degeneration (AMD) Reactivation at Home: the MONARCH study

All Faculty

15:47 Discussion